Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

Karim Chamie, MD, presents the case of a 60-year-old patient with stage 3A muscle-invasive bladder cancer (MIBC) and explains her risk of disease recurrence and whether the case is similar to the patients he typically sees in his clinical practice.

Now Viewing

EP: 1.Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP: 2.Determining Cisplatin Eligibility for Patients with MIBC

EP: 3.Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP: 4.Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP: 5.Case 2 Presentation: A 77-Year-Old Man With MIBC

EP: 6.Unmet Needs and Clinical Challenges in the Management of MIBC

EP: 7.Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP: 8.Clinical Pearls for Community Urologists Treating Patients with MIBC

Related Videos

Related Content

Advertisement

March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke

"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.

December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

March 14th 2025

What determines the optimal urinary diversion?

Anne K. Schuckman, MD

"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.

March 13th 2025

Expanded Access Program for recombinant BCG launches at first US site

Hannah Clarke

There are also 60 sites in the process of launching the EAP.

Related Content

Advertisement

March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke

"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.

December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

March 14th 2025

What determines the optimal urinary diversion?

Anne K. Schuckman, MD

"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.

March 13th 2025

Expanded Access Program for recombinant BCG launches at first US site

Hannah Clarke

There are also 60 sites in the process of launching the EAP.